01 AI-Assisted Genotype-to-Phenotype Interpretation The North America Pharmacogenomics Market analysis shows that AI-assisted interpretation is becoming more relevant as laboratories and healthcare providers handle larger volumes of genetic variants and drug-response information. The transition toward automated genotype-to-phenotype interpretation supports faster translation of genetic results into clinically meaningful metabolizer categories and treatment recommendations, while a 2025 University of Florida implementation study described structured genomic data and clinical decision-support tools within its Epic Genomics module. This shift supports faster interpretation of complex pharmacogenomic results and wider use of precision prescribing.
02 Pharmacogenomics Integration with Electronic Health Records The North America Pharmacogenomics Market analysis shows that integration with electronic health records is becoming more important as providers seek to use genetic results directly during prescribing decisions. The transition toward structured PGx data and electronic clinical decision support allows test results to remain accessible and trigger drug-specific recommendations, with a 2025 UCSF program covering 56 medications and 15 genes and incorporating 233 prescribing alerts into its EHR. This integration supports point-of-care pharmacogenomic decision-making and strengthens the use of PGx testing in routine clinical workflows.
01 Pharmacogenomic Testing in Cardiovascular Care and Clinical Research on Drug-Gene Associations Drive Market Genetic variation in drug metabolism and response can affect how patients respond to medicines used for cardiovascular conditions, creating a role for pharmacogenomic testing in treatment decisions.Genotype information can help clinicians assess medication response for therapies such as clopidogrel, where CYP2C19 variants can influence antiplatelet activity.Hospitals, cardiology centers, and clinical laboratories therefore require pharmacogenomic tests that provide relevant genotype information for medication selection.For example, CYP2C19 testing can identify patients with reduced clopidogrel metabolism and support consideration of alternative antiplatelet therapy.Broader clinical use of genotype-guided cardiovascular care supports test utilization and strengthens the need for pharmacogenomic laboratory services.Clinical research on drug-gene relationships generates evidence about how genetic variants affect medication efficacy, metabolism, and adverse reactions.Validated drug-gene evidence supports the development of clinical guidelines, testing panels, and laboratory services for genotype-guided treatment.Pharmaceutical companies, research institutions, and diagnostic laboratories therefore require pharmacogenomic testing platforms and sequencing or genotyping services during clinical studies.For example, research on CYP2C19 and clopidogrel has helped establish a clinically relevant connection between genotype and antiplatelet response.A broader evidence base for drug-gene associations supports clinical adoption and creates additional opportunities for pharmacogenomic testing providers.
01 Shortage of Skilled Pharmacogenomics Professionals and Long Turnaround Times for Certain Genetic Tests Restrain Market Expansion A shortage of skilled pharmacogenomics professionals limits the capacity to interpret genetic variants and translate results into treatment decisions.Limited expertise can create delays in test interpretation and increase the workload for healthcare providers and laboratories. This workforce gap can restrict clinical adoption and slow the integration of pharmacogenomics into routine care.Long turnaround times for certain genetic tests can delay the availability of pharmacogenomic results during treatment decisions.Extended laboratory processing and reporting periods can reduce the usefulness of testing when clinicians need timely guidance for medication selection or dosing.These delays can limit physician adoption and reduce the use of pharmacogenomic testing in time-sensitive clinical settings.
01 EHR Integration and Interoperability Gaps and Variation in Testing Platforms and Result Interpretation Hinders Growth Pharmacogenomic results must connect with EHRs and clinical decision-support systems to become useful at the point of care. Differences in EHR architecture and limited interoperability increase integration work for testing companies and healthcare providers, slowing broader adoptionDifferences in test panels, variant coverage, reporting formats, and interpretation approaches can make results harder to compare across laboratories. This complexity increases workflow requirements and can discourage providers from adopting testing across multiple clinical settings.
May 2026 Foundation Medicine expanded its partnership with Fulgent Genetics to launch FoundationOne® PGx, a pharmacogenetic testing solution in the United States designed to identify clinically actionable gene-drug interactions and guide personalized cancer therapy selection and dosing.
February 2026 Merck and Mayo Clinic entered into a strategic research and development collaboration to integrate AI, genomic data, and advanced analytics for precision medicine and drug discovery, supporting the advancement of pharmacogenomics-driven therapeutic development in North America.
November 2025 Helix partnered with University Health Network's Princess Margaret Cancer Centre in Canada to implement large-scale genomic testing for up to 100,000 patients, strengthening precision medicine infrastructure and supporting broader pharmacogenomic applications in clinical care.
May 2025 Helix expanded its pharmacogenomics portfolio with the launch of new PGx tests, including the PGx Fluoropyrimidines DPYD Test and an APOE pharmacogenomic test to support personalized treatment decisions for oncology and Alzheimer's disease patients across the United States.